pharma · NASH With Fibrosis · NASH - Nonalcoholic Steatohepatitis · HEPA
Hepion Pharmaceuticals
Hepion Pharmaceuticals is a pharma organization headquartered in Morristown, USA. It trades on NYSE under ticker HEPA. Primary therapeutic focus areas include NASH With Fibrosis, NASH - Nonalcoholic Steatohepatitis, Hepa
Morristown, USA HQ
4 Employees
Public company Type
HEPA · NYSE Ticker
Company details
- Status
- Public
- HQ
- Morristown, USA
- Employees
- 4
- Programs
- 5
- Drugs
- 2
- Patents
- 1
rencofilstat, 75 mg
Phase 2 · small molecule · NASH With Fibrosis
rencofilstat, 75 mg for NASH With Fibrosis is a Phase 2 program (small_molecule) at Hepion Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code HEPA-CRV431-210
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Hepion Pharmaceuticals
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- NASH With Fibrosis
- Status
- completed
- Trials
- 1